Here are the S-1 registration statements from GeoVax Labs, Inc. Warrants (GOVXW) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow GOVXW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GOVXW filings page.
GeoVax Labs, Inc. is registering 7,639,967 shares of common stock for resale by existing investors. These shares are issuable upon exercise of May 2026 inducement and PIPE-related warrants, and the company will not receive any proceeds from resale transactions.
GeoVax may receive cash only if holders exercise the May 2026 warrants, which could generate up to approximately $8.6 million in gross proceeds. Recent financing included a May 2026 warrant exercise inducement yielding about $844,080 in net proceeds and a May 2026 private placement with roughly $2.7 million in net proceeds.
The company is a clinical-stage biotech focused on GEO‑MVA, a Modified Vaccinia Ankara vaccine candidate for mpox and smallpox, with a pivotal Phase 3 trial planned for the second half of 2026, and Gedeptin, an oncolytic gene-directed therapy moving toward Phase 2 in head and neck cancer. GeoVax has no product revenue, reported net losses of approximately $21.5 million in 2025 and $5.3 million for the three months ended March 31, 2026, and has received a going concern opinion, noting existing cash is expected to fund operations only into June 2026.